Neodyne Biosciences, Inc.
USPTO PatentsView assignee record - 18 granted patents across 5 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).
The verdict
According to USPTO PatentsView, Neodyne ranks #16,227 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 5 technology areas.
- #16,227
- of 49,997 US assignees by volume
- Top 50%
- by Innovation Score (35.1/100)
- 20.9
- avg claims per patent
- -36%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R16227 · US Corporation #16,227 · 18 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL
- GRANTS-MICRO 18 grants
- MID-PACK #16,227/49,997
- PHOTO-FINISH National Gypsum…
- CPC-NARROW A61F · 5 areas
- INNOV-THIN 35.1/100
- CLAIMS-DENSE 20.9 claims/avg
- TYPE-USCORP US Corporation
- VEL-DOWN -36% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: National Gypsum Properties, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Neodyne’s 35.1 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Neodyne
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Neodyne Biosciences · this assignee
Neodyne Biosciences · this assignee
35 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Neodyne's Innovation Score is 35.1/100 (top 50% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Neodyne?
Each dot is one of Neodyne’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neodyne’s own 20.9 claims/patent is ABOVE the 20.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Neodyne's grants concentrate
Neodyne Biosciences, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 83.3% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2016 (4 grants) versus a trough of 1 in 2021. By volume, Neodyne sits between National Gypsum Properties, LLC and Next Level Ventures LLC.
Neodyne's three-year grant acceleration
Neodyne Biosciences, Inc. shows 4 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Neodyne's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- National Gypsum P…
National Gypsum Properties, LLC
18 patents
- National Universi…
National University Hospital (Singapore) Pte Ltd
18 patents
- Nature Technology
Nature Technology Corporation
18 patents
- Nautilus Subsidia…
Nautilus Subsidiary, Inc.
18 patents
- Netskrt Systems
Netskrt Systems, Inc.
18 patents
- Neurimmune Holding
Neurimmune Holding AG
18 patents
- Next Biometrics G…
Next Biometrics Group ASA
18 patents
- Next Level Ventur…
Next Level Ventures LLC
18 patents
- Neodyne Bioscienc… ◀
Neodyne Biosciences, Inc.
18 patents
What this shows Neodyne holds 18 patents at rank #16,237, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Neodyne
By rank, the assignees closest to #16,237 in granted patent volume.
- National Gypsum Properties, LLC #16,233 · 18 patents
- National University Hospital (Singapore) Pte Ltd #16,234 · 18 patents
- Nature Technology Corporation #16,235 · 18 patents
- Nautilus Subsidiary, Inc. #16,236 · 18 patents
- Netskrt Systems, Inc. #16,238 · 18 patents
- Neurimmune Holding AG #16,239 · 18 patents
- Next Biometrics Group ASA #16,240 · 18 patents
- Next Level Ventures LLC #16,241 · 18 patents
Leaders in A61F (Filters Implantable Into Blood Vessels)
Other assignees with the most granted patents in Neodyne's primary technology class.
- The Procter & Gamble Company 1,426 in class
- Boston Scientific Scimed, Inc. 1,101 in class
- Edwards Lifesciences Corporation 1,101 in class
- DePuy Synthes Products, Inc. 851 in class
- Globus Medical, Inc. 752 in class
- Cook Medical Technologies LLC 700 in class
- Smith & Nephew, Inc. 541 in class
- Covidien LP 528 in class
Neodyne's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
35 Top 50% higher than 50% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 4 | 22.2% |
| 2017 | 4 | 22.2% |
| 2019 | 3 | 16.7% |
| 2020 | 2 | 11.1% |
| 2021 | 1 | 5.6% |
| 2022 | 1 | 5.6% |
| 2023 | 1 | 5.6% |
| 2024 | 2 | 11.1% |
Which technologies does Neodyne Biosciences, Inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Neodyne Biosciences, Inc.'s patent record in context - here's where to go next.
- Neodyne Biosciences, Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 83.3% of its portfolio - see every assignee active in that class. Explore A61F
- Ranked #16,227 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Neodyne Biosciences, Inc. against National Gypsum Properties, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 35.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.